世界の遺伝子発現解析市場動向及び予測（～2018）...市場調査レポートについてご紹介

Table Of Contents

1 Introduction (Page No. – 17)
1.1 Objectives Of The Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.5.2.1 Key Data Points From Primary Sources
1.5.3 Market Size Estimation
1.5.4 Market Forecast
1.5.5 Market Data Validation & Data Triangulation
1.6 Assumptions

2 Executive Summary (Page No. – 30)

3 Market Overview (Page No. – 33)
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Increasing Number Of Cancer Patients Globally
3.2.1.2 Increase In Investments, Funds, And Grants By Government Bodies Worldwide
3.2.1.3 Technological Advancements
3.2.1.4 Small Rnas Gaining Momentum
3.2.1.5 Gene Expression Databases To Aid Cancer Research
3.2.1.6 Use Of Microarray Technology To Aid Gene Expression Studies
3.2.1.7 Use Of Sbs Technology To Aid More Detailed Cancer Studies
3.2.2 Restraints
3.2.2.1 High Cost Of Instruments
3.2.2.2 Dearth Of Technical Expertise
3.2.3 Opportunities
3.2.3.1 Rising Opportunities In Emerging Nations
3.2.3.2 Growth In Personalized Medicine (Gene Therapy)
3.3 Market Share Analysis
3.3.1 Gene Expression Analysis Market, By Key Players
3.4 Value Chain Analysis
3.4.1 Sequencing Platforms
3.5 Gene Expression Application Market Analysis

4 Market By Segment (Page No. – 52)
4.1 Introduction

5 GEA Instrumentation Market, By Technology (Page No. – 57)
5.1 Introduction
5.2 DNA Microarrays
5.3 Real-Time Polymerase Chain Reaction (Rt-Pcr)
5.4 Next Generation Sequencing
5.5 Others
5.5.1 Serial Analysis Of Gene Expression (Sage)
5.5.2 Northern Blotting

6 GEA Consumables Market, By Product (Page No. – 67)
6.1 Introduction
6.2 DNA Chips
6.2.1 Oligonucleotides
6.2.2 CDNA
6.3 Reagents

7 GEA Services Market, By Product (Page No. – 77)
7.1 Introduction
7.2 Gene Expression Profiling Services
7.2.1 Sequencing Services
7.2.2 Microarray Services
7.2.3 Qpcr Services
7.3 Bioinfomatics Solutions
7.4 Data Analysis Software
7.5 Others

8 GEA Market, By Application (Page No. – 90)
8.1 Introduction
8.2 Diagnostics
8.3 Drug Discovery
8.4 Academic Research
8.5 Biomarkers
8.6 Others

9 Geographic Analysis (Page No. – 100)
9.1 Introduction
9.2 North America
9.2.1 Increased Funding For Medical Research
9.2.2 Increasing Number Of Cancer Patients
9.2.3 Reduction In The Cost Of Sequencing
9.3 Europe
9.3.1 Government Support, Collaborations, And Greenfield Investments To Trigger Market Growth In Turkey
9.3.2 Reduced Government Funding In Europe To Put Pressure On Science And Research Activities
9.3.3 Increasing Focus On Pharmacogenomics To Boost The Market In Europe
9.3.4 Approvals And Developments In Gene Therapy To Propel Growth In The European Region
9.3.5 The Sequencing Of 100,000 Genomes In The U.K. To Trigger Growth In The European Region
9.4 Asia
9.4.1 Growth In The Number Of Conferences And Exhibitions On Gene Expression To Boost The Asian Market
9.4.2 Dominant Presence Of Singapore In The Market
9.4.3 Gene Expression Signature For Quality Control Of Traditional Chinese Medicines
9.4.4 Activities Of Beijing Genomics Institute (Bgi) Likely To Catapult The Chinese Market
9.4.5 Collaborations Between Established Players And Local Organisations In China To Drive The Market
9.4.6 The Rise Of The Indian Genomics Market
9.4.7 Japan’s Increasing Focus On Cancer Research
9.5 Rest Of The World (ROW)
9.5.1 Funding Scenario In Middle East And Pacific Countries
9.5.2 Increasing Focus On Hiv/Aids Genetic Resarch In Africa
9.5.3 Focus Of South American Countries On Genomic Research To Imporve Public Health
9.5.4 Growing Brazilian Market And Commitment To Gene Related Research To Boost The Market
9.5.5 Growing Need Of Gene Expression Profiling To Understand And Combat Cancer In South America And Pacific Countries Is Likely To Propel The Market Growth

10 Competitive Landscape (Page No. – 146)
10.1 Introduction
10.2 New Product Launch
10.3 Agreements, Partnerships, Collaborations & Joint Ventures
10.4 Mergers & Acquisitions
10.5 Expansion

11 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* (Page No. – 156)
11.1 Affymetrix, Inc.
11.2 Agilent Technologies
11.3 Bio-Rad Laboratories, Inc.
11.4 Ge Healthcare (Subsidiary Of General Electric Company)
11.5 Illumina, Inc.
11.6 Life Technologies
11.7 Luminex Corporation
11.8 Oxford Gene Technology, Inc.
11.9 Perkinelmer, Inc.
11.10 Qiagen N.V.
11.11 Roche Diagnostics Corporation
*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.